Bernadette Coles

Bernadette Coles

Auto-generated profile, based on publicly available information

Bernadette Coles

Cardiff University

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2004 in BJU International
Verified
Journal Article
Open access
PDF file
MSM D Shelley
M D Shelley
TWT.J. Wilt
T.J. Wilt
JCJ. Court
J. Court
BCB. Coles
B. Coles
HKH. Kynaston
H. Kynaston
MMM D Mason
M D Mason
The first paper in this section is a meta‐analysis of randomized trials into the effect of two intravesical agents used to reduce tumour recurrence in high‐risk superficial bladder cancer. This is the highest level of evidence‐based medicine and the results presented here suggest that intravesical BCG is superior to mitomycin C. There was no difference in the effect of the two agents on disease progression or survival. In a study from Amsterdam and Rome, the authors describe a phase I trial into the toxicity and safety of intravesical gemcitabine, and found that it was well tolerated with no systemic toxicity. In a paper from Taiwan the link between viral infections and tumour foundation is evaluated, in this case specifically infections with the Epstein‐Barr virus and its correlation with urothelial cancer. The authors found that there was indeed a strong association between infection with this virus and a considerable proportion of primary urothelial TCCs. OBJECTIVE: To assess, in a systematic review and meta‐analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette‐Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium‐ to high‐risk Ta and T1 bladder cancer. METHODS: The major medical databases were searched comprehensively up to June 2003, and relevant journals hand‐searched for randomized controlled trials, in any language, that compared intravesical mitomycin C with BCG in medium‐ to high‐risk patients with Ta or T1 bladder cancer. RESULTS: Twenty‐five articles were identified but only seven were considered eligible for the analysis. This represented 1901 evaluable patients in all, 820 randomized to mitomycin C and 1081 to BCG. Six trials had sufficient data for meta‐analysis and included 1527 patients, 693 in the mitomycin and 834 in the BCG arm. There was no significant difference between mitomycin C and BCG for tumour recurrence in the six trials, with a weighted mean log hazard ratio, LHR, (variance) of −0.022 (0.005). However, there was significant heterogeneity between trials ( P = 0.001). A subgroup analysis of three trials that included only high‐risk Ta and T1 patients indicated no heterogeneity ( P = 0.25) and a LHR for recurrence of −0.371 (0.012). With mitomycin C used as the control in the meta‐analysis, a negative ratio is in favour of BCG and, in this case, was highly significant ( P < 0.001). The seventh trial (in abstract form only) used BCG in low doses for two arms of the trial (27 mg and 13.5 mg) compared with a standard dose of mitomycin C (30 mg), and reported a significantly lower recurrence rate with BCG (27 mg) than for mitomycin C ( P = 0.001). Only two trials included sufficient data to analyse disease progression and survival, representing 681 patients (338 randomized to BCG and 343 to mitomycin C). There was no significant difference between mitomycin C and BCG for disease progression, with a LHR of 0.044 (0.04) ( P = 0.16), or survival, at −0.112 (0.03) ( P = 0.50). Adverse events were slightly more frequent with BCG. Local toxicity (dysuria, cystitis, frequency and haematuria) were associated with both mitomycin C (30%) and BCG (44%). Systemic toxicity, e.g. chills, fever and malaise, occurred with both agents (12% and 19%, respectively) although skin rash was more common with mitomycin C. CONCLUSION: Tumour recurrence was significantly lower with intravesical BCG than with mitomycin C only in those patients at high risk of tumour recurrence. However, there was no difference in disease progression or survival, and the decision to use either agent might be based on adverse events and cost.

1 August 2001 in BJU International
Verified
Journal Article
Open access
PDF file
MSM D Shelley
M D Shelley
HKH. Kynaston
H. Kynaston
JCJ. Court
J. Court
TWT.J. Wilt
T.J. Wilt
BCB. Coles
B. Coles
MMM D Mason
M D Mason
Objective To assess, in a systematic review, the effectiveness of intravesical bacillus Calmette‐Guérin (BCG) in preventing tumour recurrence in patients with medium/high risk Ta and T1 bladder cancer. Patients and methods An electronic database search of Medline, Embase, DARE, the Cochrane Library, Cancerlit, Healthstar and BIDS was undertaken, plus hand searching of the Proceedings of ASCO, for randomized controlled trials, in any language, comparing transurethral resection (TUR) alone with TUR followed by intravesical BCG in patients with Ta and T1 bladder cancer. Results The search identified 26 publications comparing TUR with TUR + BCG. Six trials were considered acceptable, representing 585 eligible patients, 281 in the TUR‐alone group and 304 in the TUR + BCG group. The major clinical outcome chosen was tumour recurrence. The weighted mean log hazard ratio for the first recurrence, taken across all six trials, was −0.83 (95% confidence interval −0.57 to −1.08, P < 0.001), which is equivalent to a 56% reduction in the hazard, attributable to BCG. The Peto odds ratio for patients recurring at 12 months was 0.3 (95% confidence interval of 0.21–0.43, P < 0.001), significantly favouring BCG therapy. Manageable toxicities associated with intravesical BCG were cystitis (67%), haematuria (23%), fever (25%) and urinary frequency (71%). No BCG‐induced deaths were reported. Conclusion TUR with intravesical BCG provides a significantly better prophylaxis of tumour recurrence in Ta and T1 bladder cancer than TUR alone. Randomized trials are still needed to address the issues of BCG strain, dose and schedule, and to better quantify the effect on progression to invasive disease.

1 February 2009 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MSM D Shelley
M D Shelley
SKS. Kumar
S. Kumar
TWT. Wilt
T. Wilt
JSJ. Staffurth
J. Staffurth
BCB. Coles
B. Coles
MMM D Mason
M D Mason

11 December 2006 in Cancer
Verified
Journal Article
Closed access
PDF file
PHPatricia Harnden
Patricia Harnden
MSMichael D. Shelley
Michael D. Shelley
HCHayley Clements
Hayley Clements
BCBernadette Coles
Bernadette Coles
RTR. Sandy Tyndale‐Biscoe
R. Sandy Tyndale‐Biscoe
MMMalcolm D. Mason
Malcolm D. Mason

1 September 2012 in Genetics in Medicine
Verified
Journal Article
Closed access
JHJennifer S. Hilgart
Jennifer S. Hilgart
JHJulie A. Hayward
Julie A. Hayward
BCBernadette Coles
Bernadette Coles
RIRachel Iredale
Rachel Iredale

18 October 2006 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SKSatish Kumar
Satish Kumar
MSMike Shelley
Mike Shelley
CHCraig Harrison
Craig Harrison
BCBernadette Coles
Bernadette Coles
TWTimothy J. Wilt
Timothy J. Wilt
MMMalcolm Mason
Malcolm Mason